Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
hydralazine (apresoline) (1 trial)
ranibizumab (lucentis) (1 trial)
Diabetic Retinopathy (Phase 2)
Edema (Phase 2)
Geographic Atrophy (Phase 3)
Macular Degeneration (Phase 3)
Macular Edema (Phase 2)
Retinal Diseases (Phase 2)
Trials (2 total)
Trial APIs (2 total)